摘要
目的 观察吉西他滨联合顺铂方案（GP方案）治疗晚期非小细胞肺癌的疗效及不良反应.方法 对病理证实的36例晚期非小细胞肺癌患者,采用吉西他滨联合顺铂进行化疗.吉西他滨1000 mg/m2静注第1、8d,顺铂75 mg/m2分3d静脉滴注.21 d为1周期,化疗2周期进行疗效评价1次.所有患者均接受6个周期化疗.结果 36例患者均可评价疗效和药物不良反应.其中CR 1例,PR 14例,SD 14例,PD 7例,总有效率（CR＋ PR）为41.7％.疾病控制率（CR＋ PR＋ SD）为81％.产生不良反应主要和化疗药物有关,多为Ⅰ～Ⅱ度.具体表现为白细胞减少,血小板减少,均为轻度.结论 吉西他滨联合顺铂治疗晚期非小细胞肺癌疗效可靠,不良反应较轻,安全性和耐受性好,值得临床推广.
Objective To observe the therapeutic effect and side effects of gemcitabine combined with cisplatin for the treatment of advanced nonsmall cell lung cancer（NSCLC）. Methods The 36 patients pathologically confirmed as advanced NSCLC were given gemcitabine on day 1 and 8 at a dose of 1000mg/m2 and cisplatin on day 1 to 3 at a dose of 75 mg/m2. One treatment cycle covered 3 weeks and the effects were evaluated after 2 cycles. All patients received chemotherapy of 6 cycles. Results The 36 patients were all eligible for effectiveness and side effects analysis, complete response（CR） was observed in 1 patient,partial response（PR） in 14 patients, stable disease（SD） in 14 patients, and progressive disease（PD） in 7 patients. The total response rate was 41.7%, and the disease control rate was 81%. Adverse reactions mainly and chemotherapy drugs ,mostly Ⅰ - Ⅱ degree. Specific performance as leukopenia, thrombocytopenia, were mild. Conclusion Gemcitabine combined with cisplatin in treatment of advanced non small ceil lung cancer is reliable,less adverse reactions, safety and good tolerance,is worth the clinical promotion.
出处
《哈尔滨医药》
2014年第3期180-181,共2页
Harbin Medical Journal
关键词
晚期非小细胞肺癌
吉西他滨
顺铂
Advanced nonsmall cell lung cancer
Gemcitabine
Cisplatin
